On August 7, WUXI APPTEC rose 3.12% in regular trading, trading at HKD 185.9/share, with turnover of HKD 159 million, extending its recent strong momentum.

On the news front, the company released its interim report on August 3, reporting H1 revenue of RMB 28.90 billion, up 38.93% year-over-year, with adjusted net profit of RMB 11.57 billion, surging 83.2% year-over-year, marking the first time half-year profit exceeded RMB 10 billion. Full-year revenue guidance was significantly raised from RMB 51.3-53.0 billion to RMB 58.5-60.5 billion. Following the results, Citi raised its target price to HKD 215, Bank of America to HKD 204.3, and JPMorgan noted Q2 revenue and adjusted net profit beat estimates by 25% and 47% respectively. Additionally, global pharmaceutical giant Eli Lilly posted H1 revenue growth of 51.22% year-over-year, further validating the high prosperity of the global innovative drug supply chain, with CXO upstream segments positioned to benefit first.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)